DNDN's manipulations/games are not any different from other biotech stocks. For example: Imcl from $.50 to $75 back to $6 to $87 and now at $47 on its way to $100+
DNDN is in a "play" now (assuming data is good): - short-hedge funds must get out - long institutions must get in - brokarage houses need as much trading as possible
Consequently, ALL big players were pushing down.
PS Analysts are working for & paid by these big players. So do not expect any honest and substantive report from them: retail investor paid nothing and should not expect something (except BS) in return!!!